Kidney cancer drug safety checked in patients with poor kidney function

NCT ID NCT07117409

Terminated Knowledge-focused Sponsor: Azienda USL Reggio Emilia - IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at the safety of the cancer drug nivolumab in people with metastatic kidney cancer who also have kidney failure. Researchers planned to compare side effects in 81 patients with different levels of kidney function. However, the study was terminated early, so the findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab
What this could lead to: If successful, this could help doctors understand how safe nivolumab is for kidney cancer patients with poor kidney function.
What could go wrong: This is a small, terminated observational study, so it may not provide clear answers. The results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma kidney failure renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC RENAL CELL CARCINOMA

Contacts and locations

Locations

Azienda USL IRCCS di Reggio Emilia

Reggio Emilia, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.